Cerus Corporation (CERS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cerus Corporation (CERS) has a cash flow conversion efficiency ratio of -0.045x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.05 Million) by net assets ($68.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cerus Corporation (CERS) balance sheet quality index to measure how much of total assets are equity-financed.
Cerus Corporation - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Cerus Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CERS cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Cerus Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cerus Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yonker Environmental Protect
SHE:300187
|
0.097x |
|
C&C Group PLC
F:GCC
|
0.023x |
|
Guangdong Ganhua Science & Industry Co Ltd
SHE:000576
|
-0.009x |
|
EVS Broadcast Equipment SA
BR:EVS
|
-0.014x |
|
Harson Trading China Co Ltd
SHG:603958
|
0.049x |
|
Better Home & Finance Holding Company
NYSE:BETR
|
-0.797x |
|
Design Therapeutics Inc
NASDAQ:DSGN
|
-0.056x |
|
D&O Home Collection Co Ltd
SHE:002798
|
0.039x |
Annual Cash Flow Conversion Efficiency for Cerus Corporation (1997–2025)
The table below shows the annual cash flow conversion efficiency of Cerus Corporation from 1997 to 2025. For the full company profile with market capitalisation and key ratios, see CERS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $64.97 Million | $11.36 Million | 0.175x | -12.42% |
| 2024-12-31 | $56.90 Million | $11.36 Million | 0.200x | +124.72% |
| 2023-12-31 | $53.44 Million | $-43.17 Million | -0.808x | -116.20% |
| 2022-12-31 | $68.56 Million | $-25.61 Million | -0.374x | +5.70% |
| 2021-12-31 | $85.62 Million | $-33.92 Million | -0.396x | +1.63% |
| 2020-12-31 | $103.81 Million | $-41.81 Million | -0.403x | +64.92% |
| 2019-12-31 | $57.05 Million | $-65.50 Million | -1.148x | -210.54% |
| 2018-12-31 | $84.52 Million | $-31.25 Million | -0.370x | +72.44% |
| 2017-12-31 | $38.94 Million | $-52.23 Million | -1.341x | -44.81% |
| 2016-12-31 | $57.79 Million | $-53.53 Million | -0.926x | -71.69% |
| 2015-12-31 | $94.77 Million | $-51.13 Million | -0.540x | +43.47% |
| 2014-12-31 | $41.71 Million | $-39.81 Million | -0.954x | -52.43% |
| 2013-12-31 | $42.80 Million | $-26.80 Million | -0.626x | +14.03% |
| 2012-12-31 | $19.11 Million | $-13.92 Million | -0.728x | +14.67% |
| 2011-12-31 | $18.31 Million | $-15.63 Million | -0.854x | -43.56% |
| 2010-12-31 | $23.73 Million | $-14.11 Million | -0.595x | +13.03% |
| 2009-12-31 | $21.45 Million | $-14.66 Million | -0.684x | +32.16% |
| 2008-12-31 | $34.28 Million | $-34.55 Million | -1.008x | -61.36% |
| 2007-12-31 | $59.89 Million | $-37.40 Million | -0.625x | -329.42% |
| 2006-12-31 | $100.97 Million | $-14.69 Million | -0.145x | +65.68% |
| 2005-12-31 | $35.27 Million | $-14.95 Million | -0.424x | +28.46% |
| 2004-12-31 | $21.49 Million | $-12.73 Million | -0.592x | +46.92% |
| 2003-12-31 | $52.53 Million | $-58.62 Million | -1.116x | -12.62% |
| 2002-12-31 | $56.17 Million | $-55.65 Million | -0.991x | -140.40% |
| 2001-12-31 | $106.75 Million | $-44.00 Million | -0.412x | -5.41% |
| 2000-12-31 | $81.92 Million | $-32.03 Million | -0.391x | +61.25% |
| 1999-12-31 | $33.00 Million | $-33.30 Million | -1.009x | +86.48% |
| 1998-12-31 | $1.30 Million | $-9.70 Million | -7.462x | -911.35% |
| 1997-12-31 | $22.50 Million | $-16.60 Million | -0.738x | -- |
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offer… Read more